Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen is viewed favorably because the recent debt offering extends runway into 2028, materially reducing near-term financing risk and supporting continued execution across its retinal and gene therapy pipeline. Net proceeds were about $112.6M before retirement of Avenue debt, or roughly $80M net, with an additional ~$50M potentially available from Janus Henderson warrants if exercised, while a Stargardt Priority Review Voucher could further unlock monetization. Ongoing partnership discussions may also provide non-dilutive funding, reinforcing balance-sheet flexibility as it advances its modifier gene therapy, retinal disease, regenerative medicine, and vaccine platforms.

Ocugen is burdened by a highly uncertain, capital-intensive pipeline in which commercialization depends on risky gene-therapy assets that still face financing, regulatory, manufacturing, and intellectual-property hurdles. The September 3, 2026 DMC review of GARDian3 for OCU410ST was especially concerning, as it cited a negative direction of treatment effect in the interim sample and only recommended continuing the study to resolve a baseline lesion-size imbalance, leaving approval timing and eventual efficacy unresolved. With 63 subjects enrolled, 26 assessed at interim, and management yet to announce its regulatory strategy, the company’s path to meaningful revenue remains fragile and could require additional testing or funding before any launch.